Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln

Cumberland Pharmaceuticals

04/11/2025 22:11

Overview

Cumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last year

Company reports Q3 net loss of $1.9 mln

Cumberland partners with RedHill to commercialize Talicia, expanding product portfolio

Outlook

Company did not provide specific financial guidance for future quarters

Result Drivers

PRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolio

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$8.30 mln
Q3 Adjusted EPS
-$0.06
Q3 Net Income
-$1.9 mln
Q3 Operating Expenses
$10.3 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nPnb9ThCHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)